Christopher Davis
Addiction Medicine · York, PANPI 1144473208
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $202,515 of the $226,098 with a category attached, or 89.6%. Alkermes, Inc. accounts for 99.8% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $98,380 and has fallen 99.8% since, to $154 in 2025. Among addiction medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 375 payments — averaging $602.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$226K
- Gilead$75
- Corium, LLC$63
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$53
- Sanofi-aventis U.S. LLC$41
- Braeburn Inc.$28
- plus $97 from 6 others
Across 1 payment — averaging $48,602 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$49K
What the payments were for
- Speaking & faculty fees$202,51590%
- Travel & lodging$18,2578%
- Food & beverage$5,3112%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 354 | $225,741 |
| Gilead | 4 | $75 |
| Corium, LLC | 4 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $53 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Braeburn Inc. | 2 | $28 |
| Abbott | 1 | $23 |
| Medtronic | 1 | $16 |
| Ardelyx, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Amgen | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$219,940
How this compares
$226,098 in reported general payments places this provider in the 95th percentile of 82 addiction medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 131 | $30,391 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 24 | $12,261 |
| Buprenorphine | 12 | $569 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $363 |
| Trazodone Hcl | 39 | $243 |
| Alprazolam | 24 | $201 |
| Bupropion XlBupropion Hcl | 11 | $200 |
| Duloxetine Hcl | 14 | $156 |
| Methadone Hcl | 12 | $144 |
| Pilocarpine Hcl | 12 | $98 |
| Propranolol Hcl | 12 | $77 |
| Mirtazapine | 12 | $41 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in York
- Stephen MoenningYork$275
- Karen SeesKane$928K
- William SantoroWest Reading$93K
- Philip MooreLemoyne$6K
- Carol LudolphHuntingdon Valley$5K
- Henry LuuWest Chester$5K
- Bernard HarrisNewtown Square$4K
- Jacques ChellyPittsburgh$4K
- Michael Halldu Bois$4K
- Adam ScioliWernersville$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.